MIT Technology Review discusses research estimating a 71% increase in anorexia nervosa and bulimia nervosa incidence from 1990 to 2023 alongside experts’ concerns about GLP-1 weight-loss drug misuse. The long-term estimates, modeled from 204 countries and territories, do not show that these drugs caused the increase. In a separate small study, 30% of participants with eating disorders had used GLP-1 drugs and 10% appeared to have misused them. Guidelines cited in the article recommend screening before prescribing, patient education and ongoing monitoring. Restrictive eating or symptom changes warrant discussion with the prescriber rather than unsupervised dose increases or discontinuation.